AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9440757 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-FU continuous intravenous infusion (CI)
Number of subjects: 1219
Study 9440757 — intervention group
Group type: COMPARATOR
Intervention: 5-FU bolus administration
Number of subjects: 1219
Study 7787380 — intervention group
Group type: EXPERIMENTAL
Intervention: Employment and retirement patterns, attitudes to work and retirement, involvement in leisure or recreational programmes; no specific intervention mentioned.
Number of subjects: 0
Study 7787380 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre‐retirement programmes including transition and choice‐making skills; no specific dosage or duration mentioned.
Number of subjects: 0
Study 1969290 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 5 micrograms kg‐1 before induction of anaesthesia
Number of subjects: 32
Study 1969290 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl administered i.v. before propofol infusion
Number of subjects: 32
Study 492905 — intervention group
Group type: EXPERIMENTAL
Intervention: Line-length change with tone (auditory input)
Number of subjects: 48
Study 492905 — intervention group
Group type: COMPARATOR
Intervention: Line-length change without tone (no auditory input)
Number of subjects: 48
Study 29909704 — intervention group
Group type: EXPERIMENTAL
Intervention: Ringer's solution plus oral fluids
Number of subjects: 201
Study 29909704 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextrose solution 5% plus oral fluids
Number of subjects: 201
Study 29909704 — intervention group
Group type: COMPARATOR
Intervention: Oral fluids alone
Number of subjects: 201
Study 30668631 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-Oriented Recovery Enhancement (MORE)
Number of subjects: 57
Study 30668631 — intervention group
Group type: COMPARATOR
Intervention: Active support group (control)
Number of subjects: 57
Study 28914272 — intervention group
Group type: EXPERIMENTAL
Intervention: Video intervention (n = 59)
Number of subjects: 119
Study 28914272 — intervention group
Group type: COMPARATOR
Intervention: Usual care (n = 60)
Number of subjects: 119
Study 25819269 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium Respimat 5 μg once daily
Number of subjects: 463
Study 25819269 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 463
Study 24314359 — intervention group
Group type: EXPERIMENTAL
Intervention: TAK-085 2 g (2 g once daily)
Number of subjects: 503
Study 24314359 — intervention group
Group type: EXPERIMENTAL
Intervention: TAK-085 4 g (2 g twice daily)
Number of subjects: 503
Study 24314359 — intervention group
Group type: COMPARATOR
Intervention: EPA-E 1.8 g (0.6 g three times daily)
Number of subjects: 503
Study 24314359 — intervention group
Group type: EXPERIMENTAL
Intervention: TAK-085 2 g
Number of subjects: 503
Study 24314359 — intervention group
Group type: EXPERIMENTAL
Intervention: TAK-085 4 g
Number of subjects: 503
Study 24314359 — intervention group
Group type: COMPARATOR
Intervention: EPA-E 1.8 g
Number of subjects: 503
Study 21725957 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovenous laser ablation
Number of subjects: 500
Study 21725957 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation
Number of subjects: 500
Study 21725957 — intervention group
Group type: EXPERIMENTAL
Intervention: Foam sclerotherapy
Number of subjects: 500
Study 21725957 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical stripping
Number of subjects: 500
Study 19463427 — intervention group
Group type: COMPARATOR
Intervention: CoStar (paclitaxel-eluting stent)
Number of subjects: 246
Study 19463427 — intervention group
Group type: COMPARATOR
Intervention: SymBio (dual elution stent)
Number of subjects: 246
Study 19463427 — intervention group
Group type: COMPARATOR
Intervention: Corio (pimecrolimus-eluting stent)
Number of subjects: 246
Study 17370494 — intervention group
Group type: EXPERIMENTAL
Intervention: O3 acupoint injection (30 microg/mL)
Number of subjects: 120
Study 17370494 — intervention group
Group type: COMPARATOR
Intervention: Electroacupuncture (EA)
Number of subjects: 120
Study 17370494 — intervention group
Group type: COMPARATOR
Intervention: Danggui point injection
Number of subjects: 120
Study 15049986 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin 1-8 mg once daily
Number of subjects: 210
Study 15049986 — intervention group
Group type: COMPARATOR
Intervention: Alfuzosin 5-10 mg divided in two or three daily doses
Number of subjects: 210
Study 11269737 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-FU (370 mg/m2 i.v. over 1 h, days 2-6)
Number of subjects: 22
Study 9517642 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride 10 mg t.i.d. for 2 weeks
Number of subjects: 330
Study 9517642 — intervention group
Group type: EXPERIMENTAL
Intervention: Nizatidine 300 mg at night for 2 weeks
Number of subjects: 330
Study 9517642 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 330
Study 9710032 — intervention group
Group type: EXPERIMENTAL
Intervention: MRS of abnormal white matter
Number of subjects: 5
Study 9710032 — intervention group
Group type: EXPERIMENTAL
Intervention: Histopathology findings
Number of subjects: 5
Study 9710032 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI findings
Number of subjects: 5
Study 9710032 — intervention group
Group type: EXPERIMENTAL
Intervention: Autopsy findings
Number of subjects: 5
Study 2652864 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoconazole high dose (H.D.)
Number of subjects: 28
Study 195190 — intervention group
Group type: EXPERIMENTAL
Intervention: CL 88,277 (250 mg, 1 ml administered three times a day plus one dose prior to challenge and for six consecutive post-challenge days)
Number of subjects: 20
Study 195190 — intervention group
Group type: COMPARATOR
Intervention: PEG-400 (56% polyethylene glycol, solvent of CL 88,277)
Number of subjects: 20
Study 195190 — intervention group
Group type: EXPERIMENTAL
Intervention: CL 88,277
Number of subjects: 20
Study 195190 — intervention group
Group type: COMPARATOR
Intervention: PEG-400
Number of subjects: 20
Study 31276672 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrow-band imaging (NBI)
Number of subjects: 272
Study 31276672 — intervention group
Group type: COMPARATOR
Intervention: Linked color imaging (LCI)
Number of subjects: 272
Study 29749716 — intervention group
Group type: EXPERIMENTAL
Intervention: Test dalfampridine tablet (generic formulation)
Number of subjects: 27
Study 29749716 — intervention group
Group type: COMPARATOR
Intervention: Branded dalfampridine tablet (reference formulation)
Number of subjects: 27
Study 28829368 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg of grape and apple polyphenols
Number of subjects: 48
Study 28829368 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 25651247 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous magnesium sulfate
Number of subjects: 1700
Study 25651247 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1700
Study 23780354 — intervention group
Group type: EXPERIMENTAL
Intervention: OZ‐PG: ozonized propylene glycol
Number of subjects: 50
Study 23780354 — intervention group
Group type: EXPERIMENTAL
Intervention: CH/CPMC: calcium hydroxide/camphorated paramonochlorophenol
Number of subjects: 50
Study 23780354 — intervention group
Group type: EXPERIMENTAL
Intervention: OZ‐PG/CH: ozonized PG/CH
Number of subjects: 50
Study 23780354 — intervention group
Group type: COMPARATOR
Intervention: PC: positive control group (no medication)
Number of subjects: 50
Study 23780354 — intervention group
Group type: COMPARATOR
Intervention: NC: negative control group (no contamination)
Number of subjects: 50
Study 21669376 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based COPD population screener (COPD-PS)
Number of subjects: 1006
Study 21669376 — intervention group
Group type: COMPARATOR
Intervention: Paper-and-pencil COPD population screener (COPD-PS)
Number of subjects: 1006
Study 21669376 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based COPD-PS
Number of subjects: 1006
Study 21669376 — intervention group
Group type: COMPARATOR
Intervention: Paper-and-pencil COPD-PS
Number of subjects: 1006
Study 21669376 — intervention group
Group type: EXPERIMENTAL
Intervention: Subgroup analyses on smoking status, presence of COPD, and shortness of breath
Number of subjects: 1006
Study 19707999 — intervention group
Group type: EXPERIMENTAL
Intervention: Geriatric psychiatry unit
Number of subjects: 0
Study 19707999 — intervention group
Group type: COMPARATOR
Intervention: General psychiatry unit
Number of subjects: 0
Study 16681659 — intervention group
Group type: EXPERIMENTAL
Intervention: Punch incision
Number of subjects: 60
Study 16681659 — intervention group
Group type: COMPARATOR
Intervention: Elliptical excision
Number of subjects: 60
Study 14975461 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy of half-dose reteplase and abciximab
Number of subjects: 2633
Study 14975461 — intervention group
Group type: COMPARATOR
Intervention: Reteplase
Number of subjects: 2633
Study 11725230 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment (lumbar fusion)
Number of subjects: 294
Study 11725230 — intervention group
Group type: COMPARATOR
Intervention: Nonsurgical treatment (physical therapy)
Number of subjects: 294
Study 9387956 — intervention group
Group type: EXPERIMENTAL
Intervention: Preterm infants
Number of subjects: 61
Study 9387956 — intervention group
Group type: EXPERIMENTAL
Intervention: Plethysmography
Number of subjects: 61
Study 8204228 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic calcium channel blockers
Number of subjects: 36
Study 8204228 — intervention group
Group type: COMPARATOR
Intervention: No calcium channel blockers
Number of subjects: 36
Study 3144169 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral encainide (75 to 200 mg/day)
Number of subjects: 50
Study 3144169 — intervention group
Group type: COMPARATOR
Intervention: Oral quinidine (1,200 mg/day)
Number of subjects: 50
Study 3144169 — intervention group
Group type: EXPERIMENTAL
Intervention: Encainide
Number of subjects: 50
Study 3144169 — intervention group
Group type: COMPARATOR
Intervention: Quinidine
Number of subjects: 50
Study 30934894 — intervention group
Group type: EXPERIMENTAL
Intervention: Marine n-3 polyunsaturated fatty acids (n-3 PUFA)
Number of subjects: 102
Study 30934894 — intervention group
Group type: COMPARATOR
Intervention: Soybean oil placebo
Number of subjects: 102
Study 28187222 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 µg/wk 25‐hydroxyvitamin‐D3
Number of subjects: 121
Study 28187222 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 µg/wk vitamin D3
Number of subjects: 121
Study 28187222 — intervention group
Group type: EXPERIMENTAL
Intervention: 25‐hydroxyvitamin‐D3 supplementation
Number of subjects: 121
Study 28187222 — intervention group
Group type: COMPARATOR
Intervention: Control cells (not specified dosage)
Number of subjects: 121
Study 28187222 — intervention group
Group type: COMPARATOR
Intervention: Adrenaline stimulation
Number of subjects: 121
Study 25287737 — intervention group
Group type: EXPERIMENTAL
Intervention: Regadenoson
Number of subjects: 1944
Study 25287737 — intervention group
Group type: COMPARATOR
Intervention: Adenosine
Number of subjects: 1944
Study 25287737 — intervention group
Group type: EXPERIMENTAL
Intervention: Regadenoson and Adenosine
Number of subjects: 1944
Study 23881439 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate (35 mg/week) and calcium lactate (600 mg/day)
Number of subjects: 50
Study 23881439 — intervention group
Group type: COMPARATOR
Intervention: Calcium lactate (600 mg/day)
Number of subjects: 50
Study 21809909 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese patients with COPD
Number of subjects: 364
Study 21809909 — intervention group
Group type: EXPERIMENTAL
Intervention: Overweight patients with COPD
Number of subjects: 364
Study 21809909 — intervention group
Group type: COMPARATOR
Intervention: Normal weight patients with COPD
Number of subjects: 364
Study 19808656 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous fructose (0.5 g/kg)
Number of subjects: 6
Study 19808656 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous glucose (0.5 g/kg)
Number of subjects: 6
Study 19808656 — intervention group
Group type: COMPARATOR
Intervention: Isotonic saline
Number of subjects: 6
Study 17015282 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyphenolic extract of pine bark Pycnogenol (Pyc)
Number of subjects: 0
Study 17015282 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 15799911 — intervention group
Group type: EXPERIMENTAL
Intervention: Monopolar radiofrequency ablation (n=77)
Number of subjects: 90
Study 15799911 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar radiofrequency ablation (n=13)
Number of subjects: 90
Study 15799911 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone therapy for 3 months post-surgery
Number of subjects: 90
Study 15799911 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with small preoperative left atrial diameters (<56 mm)
Number of subjects: 90
Study 15799911 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with large preoperative left atrial diameters (>=56 mm)
Number of subjects: 90
Study 11055218 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic complex including vitrectomy with ozonized normal saline
Number of subjects: 55
Study 11055218 — intervention group
Group type: COMPARATOR
Intervention: Vitrectomy with intravitreal administration of 0.4 mg gentamicin
Number of subjects: 55
Study 9752242 — intervention group
Group type: EXPERIMENTAL
Intervention: Suction endotracheal catheters numbers 12, 14, and 16
Number of subjects: 0
Study 9752242 — intervention group
Group type: EXPERIMENTAL
Intervention: Suction endotracheal catheters numbers 12 and 14
Number of subjects: 0
Study 8360731 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothermia (32-33 degrees C for 24 hours)
Number of subjects: 40
Study 8360731 — intervention group
Group type: COMPARATOR
Intervention: Normothermia (37-38 degrees C)
Number of subjects: 40
Study 3517241 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Number of subjects: 90
Study 3517241 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitoxantrone
Number of subjects: 90
Study 3517241 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin and Mitoxantrone
Number of subjects: 90
Study 30225665 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory to expiratory time ratio (I:E) of 1:1 for the first hour followed by 1:2 (group A)
Number of subjects: 32
Study 30225665 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory to expiratory time ratio (I:E) of 1:2 for the first hour followed by 1:1 (group B)
Number of subjects: 32
Study 30225665 — intervention group
Group type: COMPARATOR
Intervention: Inspiratory to expiratory time ratio (I:E) of 1:2
Number of subjects: 32
Study 29734548 — intervention group
Group type: EXPERIMENTAL
Intervention: Low glycemic index diet
Number of subjects: 37
Study 29734548 — intervention group
Group type: COMPARATOR
Intervention: Normal glycemic index diet
Number of subjects: 37
Study 24534402 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurofeedback
Number of subjects: 104
Study 24534402 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Training (CT)
Number of subjects: 104
Study 24534402 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 104
Study 23377509 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin phosphate 1.2% and tretinoin 0.025% gel (ZIANA)
Number of subjects: 30
Study 23377509 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 20584771 — intervention group
Group type: EXPERIMENTAL
Intervention: Schizophrenia (SCZ)
Number of subjects: 21
Study 20584771 — intervention group
Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 21
Study 17583431 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural ketamine and bupivacaine
Number of subjects: 53
Study 17583431 — intervention group
Group type: COMPARATOR
Intervention: Saline and bupivacaine
Number of subjects: 53
Study 16154062 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm compresses to the perineal area
Number of subjects: 1211
Study 16154062 — intervention group
Group type: EXPERIMENTAL
Intervention: Massage with lubricant
Number of subjects: 1211
Study 16154062 — intervention group
Group type: COMPARATOR
Intervention: No touching of the perineum until crowning
Number of subjects: 1211
Study 12814846 — intervention group
Group type: EXPERIMENTAL
Intervention: Coping-oriented therapy approach
Number of subjects: 0
Study 10227413 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular administration of antihypertensive medication
Number of subjects: 0
Study 10227413 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening procedure using conditional rules
Number of subjects: 0
Study 8707278 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients who remained HBeAg positive with normal aminotransferase levels (Group I)
Number of subjects: 55
Study 8707278 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients who remained HBeAg positive with elevated aminotransferase levels (Group II)
Number of subjects: 55
Study 8707278 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients who cleared HBeAg (Group III)
Number of subjects: 55
Study 8707278 — intervention group
Group type: COMPARATOR
Intervention: Interferon treated patients
Number of subjects: 55
Study 8707278 — intervention group
Group type: COMPARATOR
Intervention: Interferon responders
Number of subjects: 55
Study 1909218 — intervention group
Group type: EXPERIMENTAL
Intervention: APSAC (30 units over 5 minutes)
Number of subjects: 183
Study 1909218 — intervention group
Group type: COMPARATOR
Intervention: rt‐PA (100 mg over a 3‐hour period)
Number of subjects: 183
Study 1909218 — intervention group
Group type: EXPERIMENTAL
Intervention: APSAC
Number of subjects: 183
Study 1909218 — intervention group
Group type: COMPARATOR
Intervention: rt‐PA
Number of subjects: 183
Study 6340977 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg loprazolam
Number of subjects: 16
Study 6340977 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg nitrazepam
Number of subjects: 16
Study 6340977 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 30593884 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-completed Decision Support Tool (DST) for mental health care, including feedback on DST responses, treatment priorities, motivation assessment, and severity-matched treatment recommendations.
Number of subjects: 0
Study 30593884 — intervention group
Group type: COMPARATOR
Intervention: Usual GP care plus attention control (comparison arm).
Number of subjects: 0
Study 28570603 — intervention group
Group type: EXPERIMENTAL
Intervention: Ty21a vaccine
Number of subjects: 20
Study 28570603 — intervention group
Group type: COMPARATOR
Intervention: Non-vaccinated control
Number of subjects: 20
Study 25078946 — intervention group
Group type: EXPERIMENTAL
Intervention: Music intervention (experimental group)
Number of subjects: 97
Study 25078946 — intervention group
Group type: COMPARATOR
Intervention: Nonmusic control group
Number of subjects: 97
Study 24190345 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous repair
Number of subjects: 34
Study 24190345 — intervention group
Group type: COMPARATOR
Intervention: Open repair
Number of subjects: 34
Study 22492501 — intervention group
Group type: EXPERIMENTAL
Intervention: synthetic human PTH 1‐34 (hPTH 1‐34), injected two to three times daily for 18 months
Number of subjects: 5
Study 22492501 — intervention group
Group type: EXPERIMENTAL
Intervention: synthetic human PTH 1‐34 (hPTH 1‐34)
Number of subjects: 5
Study 19284064 — intervention group
Group type: EXPERIMENTAL
Intervention: MitraClip device
Number of subjects: 96
Study 17202798 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (induction 1.5 mg/kg, maintenance 1.5 mg kg(‐1) h(‐1))
Number of subjects: 20
Study 17202798 — intervention group
Group type: COMPARATOR
Intervention: Midazolam (induction 0.5 mg/kg, maintenance 0.1 mg kg(‐1) h(‐1))
Number of subjects: 20
Study 17202798 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups received fentanyl (induction 20 mug/kg, maintenance 10 microg kg(‐1))
Number of subjects: 20
Study 15933272 — intervention group
Group type: EXPERIMENTAL
Intervention: Toileting and walking assistance provided by research staff; intervention duration: 8 weeks.
Number of subjects: 0
Study 15933272 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified; no specific control intervention mentioned.
Number of subjects: 0
Study 15131518 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (COMB)
Number of subjects: 324
Study 15131518 — intervention group
Group type: COMPARATOR
Intervention: Nefazodone
Number of subjects: 324
Study 15131518 — intervention group
Group type: COMPARATOR
Intervention: Cognitive Behavioral Analysis System of Psychotherapy (CBASP)
Number of subjects: 324
Study 10573224 — intervention group
Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PDT) with dihaematoporphyrin ether and argon dye laser photoradiation
Number of subjects: 31
Study 10573224 — intervention group
Group type: COMPARATOR
Intervention: Nd‐YAG laser resection
Number of subjects: 31
Study 8751845 — intervention group
Group type: EXPERIMENTAL
Intervention: abciximab (ReoPro)
Number of subjects: 3
Study 8751845 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrilin
Number of subjects: 3
Study 8751845 — intervention group
Group type: EXPERIMENTAL
Intervention: tirofiban (Aggrastat)
Number of subjects: 3
Study 8751845 — intervention group
Group type: EXPERIMENTAL
Intervention: GP IIb/IIIa blockade
Number of subjects: 3
Study 8751845 — intervention group
Group type: COMPARATOR
Intervention: Standard patient care algorithms
Number of subjects: 3
Study 1835624 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron
Number of subjects: 122
Study 1835624 — intervention group
Group type: COMPARATOR
Intervention: Metoclopramide
Number of subjects: 122
Study 6753120 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirenzepine 50 mg daily
Number of subjects: 48
Study 6753120 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 30474277 — intervention group
Group type: EXPERIMENTAL
Intervention: Temperature at 26°C
Number of subjects: 32
Study 30474277 — intervention group
Group type: EXPERIMENTAL
Intervention: Temperature at 30°C
Number of subjects: 32
Study 30474277 — intervention group
Group type: EXPERIMENTAL
Intervention: Temperature at 33°C
Number of subjects: 32
Study 30474277 — intervention group
Group type: EXPERIMENTAL
Intervention: Temperature at 37°C
Number of subjects: 32
Study 30474277 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing temperature (26°C to 37°C)
Number of subjects: 32
Study 30474277 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing temperature
Number of subjects: 32